Patent ID: 7329638

Claim:
A composition, comprising: a. a first targeting component, wherein said first targeting component comprises i. a molecular recognition element, wherein said molecular recognition element has established cell specificity, wherein said molecular recognition comprises a polypeptide selected from the group consisting of Vascular Endothelial Growth Factor (VEGF) and C2B8, and ii. an anionic molecule having net negative charge, wherein said anionic molecule is heparin, wherein said anionic molecule is conjugated with said molecular recognition element; and b. a first drug delivery component, wherein said first drug delivery component comprises i. a cationic molecule having a net positive charge, wherein said cationic molecule comprises a protein transduction domain, wherein said protein transduction domain comprises a protein selected from the group consisting of TAT protein and Low Molecular Weight Protamine (LMWP) protein, and ii. at least one therapeutic agent conjugated with the cationic molecule.